Results 101 to 110 of about 66,079 (291)

CTBPro: A Next‐Generation Cholera Toxin Subunit B‐Based Neuroanatomical Tracer With Superior Brightness, Stability, and Sensitivity for Enhanced Neural Circuit Mapping

open access: yesAdvanced Science, EarlyView.
CTBPro is a next‐generation cholera toxin B–based tracer engineered by fusing CTB to the ultra‐stable fluorescent protein mBaojin. Exhibiting markedly enhanced molar brightness, CTBPro enables high‐fidelity neuronal labeling across multiple administration routes.
Xinghua Quan   +12 more
wiley   +1 more source

Comparison of rechargeable versus battery-operated insulin pumps: temperature fluctuations

open access: yesMedical Devices: Evidence and Research, 2016
Paul Vereshchetin, Thomas W McCann Jr, Navdeep Ojha, Ramakrishna Venugopalan, Brian L Levy Johnson & Johnson Diabetes Care Companies, Chesterbrook, PA, USA Abstract: The role of continuous subcutaneous insulin infusion (insulin ...
Vereshchetin P   +4 more
doaj  

Dual‐Physical‐Field Nanocatalysis: Injectable Hydrogel Enables Piezo‐Photothermal Synergy for Breast Cancer Therapy

open access: yesAdvanced Science, EarlyView.
ABSTRACT Piezocatalytic therapy (PCT) harnesses mechanical energy to generate tumor‐lethal reactive oxygen species (ROS), but its efficacy is limited by rapid electron‐hole recombination and poor intratumoral retention. To overcome these limitations, we engineered heterostructured BiOCl@CuO nanosheets embedded in an injectable, conductive ...
Can Tian   +7 more
wiley   +1 more source

The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial [PDF]

open access: hybrid, 2012
the SWITCH Study Group   +9 more
openalex   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

open access: yesAdvanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang   +6 more
wiley   +1 more source

Predictors of insulin pump initiation among people with type 2 diabetes from a US claims database using machine learning [PDF]

open access: bronze, 2023
Emily R. Hankosky   +6 more
openalex   +1 more source

SAA/FPR2 Signaling Between Pericentral Hepatocytes and Macrophages Exacerbates Zonated Liver Transplant Injury

open access: yesAdvanced Science, EarlyView.
After liver transplantation, ischemia‐reperfusion injury is more severe in pericentral regions. Multiomic analyses of human grafts and mouse models identify FOXO1 activation in pericentral hepatocytes as an upstream driver of SAA secretion. SAA recruits and activates FPR2+ macrophages, amplifying local inflammation. Amilo‐5MER inhibits SAA bioactivity,
Feng Zhang   +19 more
wiley   +1 more source

INSULIN INFUSION PUMP

open access: yesThe Lancet, 1981
H, Buchwald   +7 more
openaire   +4 more sources

Insulin Pump-Associated Adverse Events in a Brazilian Reference Center for the Treatment of Diabetes Mellitus: Proposal for a Taxonomy of Device Failures in Adults, Adolescents, and Children [PDF]

open access: bronze, 2022
Ana Lúcia Domingues Neves   +5 more
openalex   +1 more source

Brain and Liver Dual‐Targeting Oridonin Nanoparticles to Enhance Aβ Clearance for Alzheimer's Disease Therapy

open access: yesAdvanced Science, EarlyView.
We developed a nanoparticle named OAF, which simultaneously targeted to both the brain and liver via the transferrin receptor 1 (TfR1) receptor, promoting lipoprotein receptor‐related protein 1 (LRP1) expression to enhance amyloid‐beta (Aβ) clearance. In AD mice model, OAF significantly reduced Aβ deposition and cognitive impairment, while a mitigating
Wenshuai Gong   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy